Revolutionizing Drug Delivery: A Breakthrough in Programmable Chemistry
The world of medicine is constantly evolving, and the latest breakthrough in programmable chemistry could be a game-changer for drug delivery. The development of a new tool, TRACE (tetrazine release and activation by cellular enzymes), by Professor Neal K. Devaraj at the University of California San Diego, promises to revolutionize the way we approach drug development and treatment.
The key to TRACE's success lies in its ability to lock tetrazine molecules in a cage that is only released when it comes in contact with a cell-specific enzyme. This means that the drug can be targeted to specific cells, reducing side effects and improving patient outcomes. By increasing a drug's on-target efficiency, TRACE could potentially save lives and improve the quality of life for those suffering from various diseases.
But what makes this breakthrough even more exciting is the potential for bioorthogonal chemistry. This process allows researchers to perform chemical reactions in living systems without interfering with native biochemical processes. By using two designed molecules that exclusively seek each other out and "click" together to perform a chemical reaction, scientists can track and manipulate cells in real-time.
Tetrazine, a common tool in bioorthogonal chemistry, reacts quickly with partner molecules. In 2008, Devaraj and Joseph M. Fox independently reported the use of tetrazine coupling for bioorthogonal chemistry, introducing one of the fastest bioorthogonal reactions available. Today, tetrazines are found in chemistry and materials science labs around the world, as well as in human clinical trials, where they can be used as a drug-delivery mechanism.
However, tetrazine reactions can be indiscriminate, reacting across cell types in complex biological systems. This means that imaging may lack precision or drug therapeutics may act on healthy cells in addition to diseased ones. To improve efficiency, Devaraj's lab developed molecular cages that encase tetrazine, preventing them from "clicking" with other molecules. The tetrazine only becomes activated when it encounters a particular cellular enzyme that unlocks the cage.
The lab studied different tetrazine structures to determine which had the fastest uncaging rates and the quickest reaction times. They also employed a competing tetrazine-reactive scavenger to suppress activation outside target cells, further improving spatial precision and essentially programming the chemistry to work in a single cell type. By doing so, they were able to show that you can, essentially, program the chemistry in specific cell types.
The team then used real enzymes that are over-expressed in certain diseases in conjunction with doxorubicin (DOX), a potent drug used in cancer therapy with limited clinical applications due to its high cell toxicity. When comparing the tetrazine cages to a control group, DOX was only deployed when the cages came into contact with a specific enzyme. This demonstrates the potential for TRACE to improve drug efficacy with fewer side effects.
Beyond drug delivery, the team also built fluorescent probes that only light up after TRACE activation. The lab was able to show that only cells that both expressed the enzyme and the molecular tag fluoresced. Another probe was used to label the surface of cells that have high alkaline phosphatase (ALP) activity, a marker often elevated in certain tumors. The probe attached to a cell-surface "handle" and turned fluorescent only where ALP was active, allowing precise visualization of enzyme activity on live cells.
Devaraj has been researching tetrazines for nearly 20 years, and he shows no signs of stopping. Now that his lab has built the cages, he is looking for ways to improve selectivity, which may lead to increased drug efficacy with fewer side effects. He is particularly interested in the idea that you could rethink how you deliver drugs and imaging agents, and that you can do these things in the human body.
In conclusion, the development of TRACE by Professor Devaraj and his team is a significant breakthrough in programmable chemistry. By improving the efficiency of drug delivery and reducing side effects, TRACE has the potential to revolutionize the way we approach drug development and treatment. With further research and development, TRACE could potentially save lives and improve the quality of life for those suffering from various diseases.
